This is a preview of subscription content, log in via an institution to check access.
References
Mora S, Cui Y, Ridker PM. Association of HDL cholesterol and apolipoprotein A-I with incident CVD across levels of LDL cholesterol in 27, 748 women. Circulation. 2009;120:S507.
Frikke-Schmidt R et al. Cholesterol ester transfer protein genotype predicts anti-atherogenic lipid profile and decreased risk of ischemic heart disease, ischemic cerebrovascular disease, and death not attributable to HDL cholesterol alone. Circulation. 2009;120:S1175.
Ansell BJ, Navab M, Hama S, Kamranpour N, Fonarow G, Hough G, et al. Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation. 2003;108:2751–6.
Vasquez E, Sethi AA, Sampson M, Remaly AT, Chaudry H. O Cannon III R. “Dysfunctional” high-density lipoprotein despite normal cholesterol content in sedentary obese women. Circulation. 2009;120:S470.
Khera AV, Rodriques A, de la Lioera-Moya M, Rothblatt GH, Rader DJ. Serum cholesterol efflux capacity, a measure of HDL-C quality, varies according to coronary artery disease status independently of HDL-C quantity. Circulation. 2009;120:S469.
Hara T, Ishida T, Kojima Y, Hirata K-I. Inactivation of endothelial lipase increases anti-inflammatory HDL particles. Circulation. 2009;120:S469.
Besler C, Heinrich K, Rohrer L, Yonekawa K, Doerriers C, Manes C, et al. Mechanisms leading to impaired endothelial-vasoprotective properties of high density lipoprotein (HDL) in patients with coronary disease (CAD). Circulation. 2009;120:S1009.
Holy E, Stampfli SF, Akhmedov A, Camici G, Luscher TF, Tanner FC. High-density lipoprotein (HDL) from healthy subjects, but not from patients with coronary artery disease, exerts anti-thrombotic effects on human endothelial cells. Circulation. 2009;120:S1099.
Drew BG, Duffy SJ, Forbes JM, Chin-Dusting J, Kaye DM, Kemp BE, et al. High density lipoprotein modulates glucose metabolism by multiple mechanisms. Circulation. 2009;120:S468.
Barter PJ, Caulfield M, Eriksson M, Griudy SM, Kastelein JJP, Komajda M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357:2109–22.
Stroes ESG, Kastelein JJP, Benardeau A, Kuhlmann O, Blum D, Campos LA, et al. B J Pharmacol. 2009;158:1763–70.
Maugeais C, Magg C, Dernick G, Matile H, von der Mark E, Pflieger P, et al. Dalcetrapib binds to and changes the conformation of CETP in a unique manner (differing to that observed with torcetrapib). Circulation. 2009;120:S445.
Niesor EJ, Okamoto H, Naugeais C, von der Mark E, Brousse M, Blum-Kaelin D, et al. The effects of dalcetrapib on macrophage reverse cholesterol transport in a rodent model. Circulation. 2009;120:S468.
Devine PJ, Turco MA, Taylor AJ. Design and rationale of the ARBITER 6 trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol)- 6-HDL and LDL treatment strategies in atherosclerosis (HALTS). Cardiovasc Drugs Ther. 2007;21:221–5.
Taylor AJ, Villnes TC, Stanek EJ, Devine PJ, Griffen L, Miller M, et al. Extended-release niacin or ezetimibe and carotid intima–media thickness. N Engl J Med. 2009;361:2113–22.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Rosenson, R.S. Functional Assessment of HDL: Moving Beyond Static Measures for Risk Assessment. Cardiovasc Drugs Ther 24, 71–75 (2010). https://doi.org/10.1007/s10557-009-6214-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10557-009-6214-3